Deucravacitinib miss in ulcerative colitis a blow for hot target

The Phase II ulcerative colitis miss for deucravacitinib from Bristol Myers — the most advanced selective TYK2 inhibitor in the pipeline — is a blow for the hot target, but it’s a difficult indication.

Bristol Myers Squibb (NYSE:BMY) announced Thursday that deucravacitinib missed the primary efficacy endpoint of complete remission at week 12 and secondary efficacy endpoints in the Phase II LATTICE-UC study in moderate-to-severe patients. ...